生物活性 | |||
---|---|---|---|
描述 | Tubastatin A exhibits significant selectivity towards all 11 HDAC isoforms, maintaining over 1000-fold selectivity against all isoforms except HDAC8, for which it demonstrates approximately 57-fold selectivity. In assays assessing homocysteic acid (HCA)-induced neurodegeneration, Tubastatin A demonstrates dose-dependent protection against HCA-induced neuronal cell death, with significant protection observed at 5 μM and near-complete protection at 10 μM[1]. Treatment of CC12 cells with Tubastatin A results in impaired myotube formation when alpha-tubulin undergoes early hyperacetylation during the myogenic process; however, myotube elongation occurs when alpha-tubulin is hyperacetylated in mature myotubes[3]. A recent study suggests that treatment with Tubastatin A enhances cell elasticity, as demonstrated by atomic force microscopy (AFM) tests, without causing significant alterations to the actin microfilament or microtubule networks in mouse ovarian cancer cell lines, MOSE-E and MOSE-L[4]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.23mL 0.45mL 0.22mL |
11.13mL 2.23mL 1.11mL |
22.25mL 4.45mL 2.23mL |
参考文献 |
---|